A team of inventive scientists, tech entrepreneurs and pioneering practitioners working in tandem to catalyze successful health innovation.
Leadership and Investment Team
Dr. Michael Shleifer
Co-Founder, Managing
Partner
Ivan Jarry
Co-Founder
Al Hummel
Senior Partner
Thomas Fratacci
Chief Financial Officer
Daniel Martinez
VP Clinical Trials Financing
Chang Chu Chuen
Investment Analyst
Adam Deutsch
TrialCap, Chief Operating Officer
Operation Team
Rae Slattery
Finance Director
Chong Wee Khoo
Financial Controller
Hartini Ismail
HR Executive
Cindy Affandi
Graphic Designer
Advisors
Susan Dallabrida, PhD
CEO of SPRIM Consultancy
Aaron Kim
Advisor, BAC Director
Alain Mutricy
Advisor, Executive Relations
Paul Bernard
Advisor, BAC Director
Bruno Montanari
Advisor, BAC Director
Ruti Alon
Advisor, Ventures
SGI At A Glance
SPRIM Global Investments is a privately held investment company. SGI was established in 2008 following the global expansion of SPRIM Consulting & Services business.
SPRIM Global Investments leverages the funnel of SPRIM’s sourcing, screening and selection processes across the globe to identify and invest in high potential health solutions. We find dynamic young companies proposing innovative offerings and help them to accelerate their growth. These startups can, in turn, leverage the SPRIM network, enabling them to fast-track their development. Our portfolio companies have full access to SPRIM’s fellow venture company experts across the globe as well as the company’s investment vehicles.
Areas Of Focus
SPRIM Global Investments invests principally in companies that provide R&D capabilities to bring life science, biotech and medtech innovations to patients around the world. Our portfolio of R&D Service/CRO and digital technology companies are addressing many of the pain points across the different clinical stages of drug and device development. Additionally, SGI leverages its unique vantage point in clinical stages to invest in Biotech and in Medtech.
We Build Companies For The Future Of Health.
SPRIM believes in maximizing the potential of innovative digital health and life science innovations by providing scientific, clinical and entrepreneurial expertise to foster bold, new, innovative solutions to the world’s biggest health problems.
Our portfolio companies leverage the capabilities and network of SGI investments in R&D Services, Healthcare IT and digital solutions across 17 offices, strategically placed throughout Asia-Pacific, Europe and the Americas.
Headquarters
New York
545 West 25th Street,
20th Floor New York,
NY, USA 10001
Singapore
79 Science Park Drive
Level 06 Unit 01/08
CINTECH IV, Science Park 1
Singapore 118264
We invest to bring better solutions for companies to develop and commercialize their innovations in life science.
The Criteria
R&D Services/CRO and Digital Health/HCIT
From early stage to growth stage, we look for innovative services and software solutions to improve the conduct and outcomes of clinical trials, regulatory processes and commercialization of drugs and medical technologies.
Biotech
We invest in preclinical as well as clinical stage companies, primarily in neurology, oncology and fibrosis.
Medtech
We invest in medtech and digital therapeutics after tne PoC stage.
